Australia markets close in 26 minutes

Cassava Sciences, Inc. (SAVA)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
35.83+1.69 (+4.95%)
At close: 04:00PM EST
35.74 -0.09 (-0.25%)
After hours: 07:59PM EST
Full screen
Trade prices are not sourced from all markets
Previous close34.14
Open34.00
Bid35.36 x 1100
Ask35.74 x 1000
Day's range33.73 - 36.47
52-week range13.84 - 62.49
Volume1,164,203
Avg. volume2,409,714
Market cap1.495B
Beta (5Y monthly)0.08
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Dec 2012
1y target estN/A
  • GlobeNewswire

    Cassava Sciences Announces Closing of $50 Million Registered Direct Offering

    AUSTIN, Texas, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced the closing of its previously announced registered direct offering of 1,666,667 shares of its common stock, at a purchase price per share of $30, for gross proceeds of approximately $50 million. H.C. Wainwright & Co. acted as the exclusive placement agent for the offering. JonesTrading

  • GlobeNewswire

    Cassava Sciences Announces $50 Million Registered Direct Offering of Common Stock

    AUSTIN, Texas, Nov. 18, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) (the “Company” or “Cassava Sciences”), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced that it has entered into a definitive agreement with several healthcare-focused and other institutional investors for the purchase of 1,666,667 shares of its common stock, at a purchase price of $30 per share, for gross proceeds of approximately $50 million, in a registered direct offer

  • GlobeNewswire

    Cassava Sciences Reports Third Quarter Financial Results for 2022 and Business Updates

    – $174.7 Million Cash and Cash Equivalents at September 30, 2022 – – Over 650 Patients Now Enrolled in Phase 3 Program - – New Clinical Data for Simufilam in Alzheimer’s Disease Expected – AUSTIN, Texas, Nov. 07, 2022 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA), a clinical-stage biotechnology company focused on Alzheimer’s disease, today announced financial results for the third quarter ended September 30, 2022 and provided a clinical update on its Phase 3 clinical program of simuf